Chidamide in Combination With ART for Reactivation of the Latent HIV-1 Reservoir

Inclusion Criteria: * Documented HIV-1 infection * Currently receiving cART and having received cART for a minimum of 24 months, HIV-1 plasma RNA \<20 copies/mL for at least 1.5 year (excluding viral load blips) * CD4 T cell count \>350 cells/mm3 * Able, willing to give written informed consent and to adhere to therapy and to comply with time requirements for study visits and evaluations * Adequate vascular access for leukapheresis Exclusion Criteria: * Acute HIV-1 infection * Received blood transfusions or hematopoetic growth factors within 3 months receipt of compounds with HDAC inhibitor-like activity, such as valproic acid within the last 1 month. Potential participants may enroll after a 30-day washout period. * Any significant acute medical illness in the past 8 weeks * Any evidence of an active AIDS-defining opportunistic infection * Hepatitis B or C infection as indicated by the presence of Hepatitis B surface antigen (HBsAg) or hepatitis C virus RNA (HCV-RNA) in blood * Patient has the following laboratory values within 3 weeks before starting the investigational drug 1. Hepatic transaminases (AST or ALT) ≥3 x upper limit of normal (ULN) 2. Serum total bilirubin ≥1.5 ULN 3. Serum creatinine levels ≥1.5 x ULN, or calculated creatinine clearance ≤60 ml/min 4. Platelet count ≤100 x109/L 5. Absolute neutrophil count ≤1.5x109/L 6. Serum potassium, magnesium, phosphorus outside normal limits 7. Total calcium (corrected for serum albumin) or ionized calcium ≤lower normal limits * A personal history of clinically significant cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or additional risk factors for Torsades de pointes (e.g. heart failure) * History of malignancy or transplantation, including skin cancers or Kaposi sarcoma * History of diabetes mellitus * Known hypersensitivity to the components of chidamide or its analogues * Pregnancy or breast feeding, or expecting to father children within the projected duration of the study * Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial